ELGN GI
Alternative Names: ELGN-2112; ELGN-GI; NTRA-2112Latest Information Update: 11 Jun 2025
At a glance
- Originator Nutrinia
- Developer Elgan Pharma
- Class Insulins; Pancreatic hormones
- Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Gastrointestinal disorders
Most Recent Events
- 20 Feb 2025 Elgan Pharma initiated a phase III trial in Gastrointestinal disorders (In neonates) in Israel, France, Spain, the Netherlands (PO) (EudraCT2021-004890-29) (NCT05670951)
- 20 Feb 2025 Phase-III clinical trials in Gastrointestinal disorders (In neonates) in Austria (PO) (EudraCT2021-004890-29) (NCT05670951)
- 20 Feb 2025 Phase-III clinical trials in Gastrointestinal disorders (In neonates) in Sweden (PO) (EudraCT2021-004890-29) (NCT05670951)